{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:28:53Z","timestamp":1788866933835,"version":"build-2803163510"},"reference-count":43,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":165,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Cystic fibrosis (CF) is a congenital condition caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. CF-related diabetes (CFRD) is a common comorbidity among people with CF (pwCF) and is associated with increased morbidity. Previous in vitro studies have suggested that CFTR dysfunction is involved in the pathogenesis of CFRD. This prospective study aimed to evaluate the role of CFTR in glucose homeostasis by comparing glucose, insulin, C-peptide, glucagon and GLP-1 responses during an oral glucose tolerance test (OGTT) in pwCF and healthy controls and in pwCF before and after initiating elexacaftor\u2013tezacaftor\u2013ivacaftor (ETI) therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-four pwCF were enrolled, of which 18 underwent OGTT both before and after ETI initiation. Ten healthy controls were included for comparison. Plasma samples were collected at standard OGTT time points, including an additional 15 min sample. Hormonal and glucose responses during OGTT were compared across groups and in pwCF before and after starting ETI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with healthy controls, pwCF exhibited impaired glucose regulation, delayed insulin secretion, decreased insulin sensitivity index and reduced disposition index, indicating beta-cell dysfunction. In addition, p-glucagon levels were elevated in pwCF. Following ETI therapy, pwCF showed improved glucose control, increased first-phase insulin secretion and normalized glucagon secretion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings support a role for CFTR in islet hormone regulation, implicating direct effects on beta-cell function and a potential role in suppressing glucagon secretion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-25-0690","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T10:37:58Z","timestamp":1767609478000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":3,"title":["Elexacaftor\u2013tezacaftor\u2013ivacaftor enhances first-phase insulin secretion and improves glucose control in cystic fibrosis"],"prefix":"10.1530","volume":"15","author":[{"given":"Anna","family":"Edlund","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Lindberg","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Fagher","sequence":"additional","affiliation":[{"name":"3"},{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6366-2309","authenticated-orcid":true,"given":"Lisa I","family":"P\u00e5hlman","sequence":"additional","affiliation":[{"name":"1"},{"name":"5"},{"name":"6"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"2026070713515976500_bib1","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/apa.15155","article-title":"Cystic fibrosis in the year 2020: a disease with a new face","volume":"109","author":"De Boeck","year":"2020","journal-title":"Acta Paediatr"},{"key":"2026070713515976500_bib2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1164\/rccm.201403-0576OC","article-title":"Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex","volume":"191","author":"Lewis","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026070713515976500_bib3","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"key":"2026070713515976500_bib4","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD clinical practice consensus guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"2026070713515976500_bib5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0022-3476(05)80032-0","article-title":"Pancreatic endocrine function in cystic fibrosis","volume":"118","author":"Moran","year":"1991","journal-title":"J Pediatr"},{"key":"2026070713515976500_bib6","first-page":"207","article-title":"Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance","volume":"128","author":"Lanng","year":"1993","journal-title":"Acta Endocrinol"},{"key":"2026070713515976500_bib7","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2337\/diab.43.8.1020","article-title":"Insulin sensitivity in cystic fibrosis","volume":"43","author":"Moran","year":"1994","journal-title":"Diabetes"},{"key":"2026070713515976500_bib8","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jcf.2024.06.004","article-title":"Beyond insulin: unraveling the complex interplay of ER stress, oxidative damage, and CFTR modulation in CFRD","volume":"23","author":"Umashankar","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026070713515976500_bib9","article-title":"Oxidative stress and impaired insulin secretion in cystic fibrosis pig pancreas","volume":"5","author":"O\u2019Malley","year":"2022","journal-title":"Adv Redox Res"},{"key":"2026070713515976500_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98240","article-title":"Cystic fibrosis-related diabetes is caused by islet loss and inflammation","volume":"3","author":"Hart","year":"2018","journal-title":"JCI Insight"},{"key":"2026070713515976500_bib11","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2337\/dc17-1387","article-title":"Islet Interleukin-1beta immunoreactivity is an early feature of cystic fibrosis that may contribute to beta-cell failure","volume":"41","author":"Hull","year":"2018","journal-title":"Diabetes Care"},{"key":"2026070713515976500_bib12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0046-8177(84)80191-4","article-title":"Endocrine pancreas in cystic fibrosis: an immunohistochemical study","volume":"15","author":"Iannucci","year":"1984","journal-title":"Hum Pathol"},{"key":"2026070713515976500_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17404-z","article-title":"Structural abnormalities in islets from very young children with cystic fibrosis may contribute to cystic fibrosis-related diabetes","volume":"7","author":"Bogdani","year":"2017","journal-title":"Sci Rep"},{"key":"2026070713515976500_bib14","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jcf.2015.02.009","article-title":"Insulin secretion abnormalities in exocrine pancreatic sufficient cystic fibrosis patients","volume":"14","author":"Wooldridge","year":"2015","journal-title":"J Cyst Fibros"},{"key":"2026070713515976500_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1741-7015-12-87","article-title":"CFTR and Anoctamin 1 (ANO1) contribute to cAMP amplified exocytosis and insulin secretion in human and murine pancreatic beta-cells","volume":"12","author":"Edlund","year":"2014","journal-title":"BMC Med"},{"key":"2026070713515976500_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41598-017-00098-8","article-title":"CFTR is involved in the regulation of glucagon secretion in human and rodent alpha cells","volume":"7","author":"Edlund","year":"2017","journal-title":"Sci Rep"},{"key":"2026070713515976500_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242749","article-title":"Heterogeneous expression of CFTR in insulin-secreting beta-cells of the normal human islet","volume":"15","author":"Di Fulvio","year":"2020","journal-title":"PLoS One"},{"key":"2026070713515976500_bib18","doi-asserted-by":"crossref","first-page":"E200","DOI":"10.1152\/ajpendo.00333.2015","article-title":"CFTR silencing in pancreatic beta-cells reveals a functional impact on glucose-stimulated insulin secretion and oxidative stress response","volume":"310","author":"Ntimbane","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2026070713515976500_bib19","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1038\/ncomms5420","article-title":"Glucose-induced electrical activities and insulin secretion in pancreatic islet beta-cells are modulated by CFTR","volume":"5","author":"Guo","year":"2014","journal-title":"Nat Commun"},{"key":"2026070713515976500_bib20","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1210\/en.2017-00282","article-title":"Glucose-sensitive CFTR suppresses glucagon secretion by potentiating KATP channels in pancreatic islet alpha cells","volume":"158","author":"Huang","year":"2017","journal-title":"Endocrinology"},{"key":"2026070713515976500_bib21","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.cmet.2016.08.020","article-title":"Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes","volume":"24","author":"Segerstolpe","year":"2016","journal-title":"Cell Metab"},{"key":"2026070713515976500_bib22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/JOE-18-0570","article-title":"Defective exocytosis and processing of insulin in a cystic fibrosis mouse model","volume":"241","author":"Edlund","year":"2019","journal-title":"J Endocrinol"},{"key":"2026070713515976500_bib23","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1172\/JCI60610","article-title":"Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets","volume":"122","author":"Olivier","year":"2012","journal-title":"J Clin Investig"},{"key":"2026070713515976500_bib24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1042\/CS20140059","article-title":"Glycaemic regulation and insulin secretion are abnormal in cystic fibrosis pigs despite sparing of islet cell mass","volume":"128","author":"Uc","year":"2015","journal-title":"Clin Sci"},{"key":"2026070713515976500_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00424-002-0781-5","article-title":"Fast insulin secretion reflects exocytosis of docked granules in mouse pancreatic B-cells","volume":"444","author":"Olofsson","year":"2002","journal-title":"Pflugers Arch"},{"key":"2026070713515976500_bib26","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00125-003-1153-1","article-title":"Insulin granule dynamics in pancreatic beta cells","volume":"46","author":"Rorsman","year":"2003","journal-title":"Diabetologia"},{"key":"2026070713515976500_bib27","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0026-0495(89)90064-4","article-title":"Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy","volume":"38","author":"Hosker","year":"1989","journal-title":"Metabolism"},{"key":"2026070713515976500_bib28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0896-6273(00)80983-6","article-title":"Vesicle pools and Ca2+ microdomains: new tools for understanding their roles in neurotransmitter release","volume":"20","author":"Neher","year":"1998","journal-title":"Neuron"},{"key":"2026070713515976500_bib29","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.2337\/diabetes.51.2007.S60","article-title":"Signals and pools underlying biphasic insulin secretion","volume":"51","author":"Henquin","year":"2002","journal-title":"Diabetes"},{"key":"2026070713515976500_bib30","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/pedi.12700","article-title":"\u03b2-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose \u2265155 mg\/dL","volume":"19","author":"Nyirjesy","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"2026070713515976500_bib31","article-title":"The role of modulators in cystic fibrosis related diabetes","volume":"27","author":"Merjaneh","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"2026070713515976500_bib32","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1002\/ppul.26562","article-title":"Changes in glucose tolerance in people with cystic fibrosis after initiation of first-generation CFTR modulator treatment","volume":"58","author":"Ekblond","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2026070713515976500_bib33","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1007\/s00125-024-06220-6","article-title":"Insulin sensitivity, disposition index and insulin clearance in cystic fibrosis: a cross-sectional study","volume":"67","author":"Nielsen","year":"2024","journal-title":"Diabetologia"},{"key":"2026070713515976500_bib34","article-title":"The changing landscape of treatment for cystic fibrosis related diabetes","volume":"35","author":"Amini","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"2026070713515976500_bib35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000530571","article-title":"Improvements in glucose regulation in children and young people with cystic fibrosis-related diabetes following initiation of elexacaftor\/tezacaftor\/ivacaftor","volume":"97","author":"Park","year":"2024","journal-title":"Horm Res Paediatr"},{"key":"2026070713515976500_bib36","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s40618-021-01525-4","article-title":"Lumacaftor\/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion","volume":"44","author":"Colombo","year":"2021","journal-title":"J Endocrinol Investig"},{"key":"2026070713515976500_bib37","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the cystic fibrosis foundation, endorsed by the pediatric endocrine society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"2026070713515976500_bib38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1463-1326.2005.00568.x","article-title":"Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione","volume":"8","author":"Kautzky-Willer","year":"2006","journal-title":"Diabetes Obes Metab"},{"key":"2026070713515976500_bib39","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care"},{"key":"2026070713515976500_bib40","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"2026070713515976500_bib41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1530\/eje.0.1300253","article-title":"No changes of insulin sensitivity in cystic fibrosis patients with different degrees of glucose tolerance: an epidemiological and longitudinal study","volume":"130","author":"Cucinotta","year":"1994","journal-title":"Eur J Endocrinol"},{"key":"2026070713515976500_bib42","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s42255-020-00327-x","article-title":"Metabolic messengers: glucagon-like peptide 1","volume":"3","author":"Gribble","year":"2021","journal-title":"Nat Metab"},{"key":"2026070713515976500_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-76722-1","article-title":"Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs","volume":"14","author":"Gharib","year":"2024","journal-title":"Sci Rep"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/15\/1\/EC-25-0690.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/15\/1\/EC-25-0690.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0690\/504905\/ec-25-0690.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0690\/504905\/ec-25-0690.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:53:38Z","timestamp":1783446818000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/15\/1\/e250690\/75353\/Elexacaftor-tezacaftor-ivacaftor-enhances-first"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-25-0690","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"e250690"}}